Document is current

Article History

Accepted: 25 April 2024

First Online: 17 May 2024

Declarations

:

: This study was funded by UCB Pharma.

: Patric Berling and Mata Charokopou are employees of UCB Pharma. Magnus Värendh and Chiara Malmberg are employees of the Swedish Institute for Health Economics, which provides consulting services for governmental bodies, academic institutions and commercial life science enterprises, including UCB Pharma. The Swedish Institute for Health Economics is owned principally by the non-profit Bengt Jönsson Foundation for Health Economic Research. Erik Eklund has no disclosures.

: Data from non-interventional studies is outside of UCB’s data sharing policy and is unavailable for sharing.

: Not applicable.

: Not applicable.

: Not applicable.

: Due to ongoing reimbursement applications, UCB considers the model as proprietary until all processes have been completed around the globe. Specific requests can be sent and UCB will decide on a case-by-case basis whether the request can be granted.

: Mata Charokopou took the lead on the study conception and design. Material preparation, data collection and analysis were performed by Chiara Malmberg, Magnus Värendh, Patric Berling and Erik Eklund. The first draft of the manuscript was written by Chiara Malmberg and Magnus Värendh, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.